Research journal · Semaglutide
STEP 1: Semaglutide 2.4 mg for Weight Management
The pivotal weight-management trial for the approved injectable product.
STEP 1 is the pivotal weight-management trial most often cited for semaglutide. This summary describes its widely reported design and outcome, and — critically — the limits on applying it to compounded products. Specific statistics are pending confirmation of their primary-source citations during medical review.
Why this study matters
STEP 1 is frequently the source of the "about 15% weight loss" figure that circulates in GLP-1 marketing. Understanding what the trial actually studied — a specific approved product, at a specific dose, by injection, over a defined period — is essential to reading that figure correctly and to recognizing when marketing borrows it inappropriately for a different product.
Design, as widely reported
STEP 1 was a randomized, double-blind, placebo-controlled trial of once-weekly subcutaneous semaglutide 2.4 mg versus placebo, both with lifestyle intervention, in adults with overweight or obesity without diabetes, over 68 weeks. The primary focus was change in body weight. These design features are the widely reported ones; exact enrollment, endpoints, and statistics will be confirmed against the primary source at review.
Reported outcome
FDA-approved injectable products at studied doses. These outcomes do not transfer to compounded, microdose, or oral/sublingual formulations. Values pending citation confirmation at medical review.
View chart data as a table
| Trial & product | Mean weight reduction | Duration |
|---|---|---|
| STEP 1 — semaglutide 2.4mg (reported mean) | 14.9% | 68 weeks |
The widely reported headline is a mean total body-weight reduction on the order of roughly 15% over 68 weeks in the treatment group, substantially greater than placebo. This figure belongs to the approved injectable product at the 2.4 mg dose. It is the number to keep in mind — with its qualifications — whenever a compounded, microdose, or oral product implies a comparable result.
Why it doesn't transfer to compounded products
The result establishes what approved injectable semaglutide does at a studied dose. It does not establish that a compounded preparation matches that potency and consistency, that a sub-therapeutic "microdose" delivers comparable benefit, or that an oral or sublingual compounded product achieves the blood levels the injection produces. Each of those is a separate, largely unstudied question. Marketing that places the STEP 1 figure beside a compounded product invites an inference the trial doesn't support.
Practical interpretation
Read the ~15% figure as the benchmark for the approved injectable product at its studied dose, and treat any compounded product's expected outcome as uncertain unless it has its own formulation-specific evidence — which compounded products generally lack. For your own situation, what any product is likely to achieve is a clinical judgment for a prescriber, informed by the approved-product evidence but not dictated by it.
Summary pending medical review and citation confirmation. Not medical advice. Describes an FDA-approved product; compounded products are not FDA approved and their outcomes are not established by this trial.